Clal Insurance Enterprises Holdings Ltd Takes Position in VanEck Pharmaceutical ETF $PPH

Clal Insurance Enterprises Holdings Ltd acquired a new stake in VanEck Pharmaceutical ETF (NASDAQ:PPH) during the second quarter, HoldingsChannel reports. The firm acquired 325,000 shares of the company’s stock, valued at approximately $28,587,000. Clal Insurance Enterprises Holdings Ltd owned 0.06% of VanEck Pharmaceutical ETF at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in PPH. Avalon Trust Co grew its stake in shares of VanEck Pharmaceutical ETF by 0.3% in the 1st quarter. Avalon Trust Co now owns 283,685 shares of the company’s stock valued at $25,852,000 after purchasing an additional 895 shares during the last quarter. J.Safra Asset Management Corp lifted its holdings in shares of VanEck Pharmaceutical ETF by 1.7% during the second quarter. J.Safra Asset Management Corp now owns 271,620 shares of the company’s stock worth $23,759,000 after purchasing an additional 4,566 shares during the period. Adamsbrown Wealth Consultants LLC grew its position in VanEck Pharmaceutical ETF by 12.0% in the 2nd quarter. Adamsbrown Wealth Consultants LLC now owns 195,976 shares of the company’s stock valued at $17,238,000 after buying an additional 21,074 shares during the last quarter. Royal Bank of Canada increased its stake in VanEck Pharmaceutical ETF by 53.3% in the 1st quarter. Royal Bank of Canada now owns 67,596 shares of the company’s stock valued at $6,160,000 after buying an additional 23,491 shares during the period. Finally, Phoenix Financial Ltd. increased its stake in VanEck Pharmaceutical ETF by 13.8% in the 2nd quarter. Phoenix Financial Ltd. now owns 61,276 shares of the company’s stock valued at $5,390,000 after buying an additional 7,417 shares during the period.

VanEck Pharmaceutical ETF Stock Performance

Shares of VanEck Pharmaceutical ETF stock opened at $99.23 on Wednesday. VanEck Pharmaceutical ETF has a one year low of $77.67 and a one year high of $100.46. The company has a market cap of $1.23 billion, a P/E ratio of 20.21 and a beta of 0.54. The firm has a fifty day moving average of $92.25 and a two-hundred day moving average of $89.14.

VanEck Pharmaceutical ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, October 6th. Investors of record on Wednesday, October 1st were given a $0.3931 dividend. The ex-dividend date was Wednesday, October 1st. This represents a $1.57 dividend on an annualized basis and a yield of 1.6%.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.